
John Powers
Articles
-
Nov 25, 2024 |
kasu.org | John Powers
This Paramount+ series, featuring Billy Bob Thornton as a savvy veteran of the oil business, is an old-fashioned soap opera and a breezy portrait of one of the world's most influential industries.
-
Oct 4, 2024 |
wqln.org | John Powers
For most of its history, Hollywood made its money by putting stars the public liked to watch in stories that wouldn’t be worth watching without them. These days, such star-driven films are falling out of fashion — except on our streamers. That’s where you’ll find Wolfs, an AppleTV+ vehicle that features George Clooney and Brad Pitt skating through a crime plot in glamorously grizzled mode.
-
Jun 27, 2024 |
nature.com | Cameron Stewart |Alexandra Schafer |Young-Jun Park |John Powers |Davide Corti |Ralph S Baric | +1 more
AbstractEvolution of SARS-CoV-2 alters the antigenicity of the immunodominant spike (S) receptor-binding domain and N-terminal domain, undermining the efficacy of vaccines and antibody therapies. To overcome this challenge, we set out to develop a vaccine focusing antibody responses on the highly conserved but metastable S2 subunit, which folds as a spring-loaded fusion machinery.
-
May 3, 2024 |
nature.com | Elizabeth Anderson |Jennifer Diaz |Sarah R. Leist |Alexandra Schafer |John Powers |Ralph S Baric | +2 more
AbstractWhole virus-based inactivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide have been critical to the COVID-19 pandemic response.
-
Feb 20, 2024 |
nature.com | Ching-Lin Hsieh |Sarah R. Leist |John Powers |Jonathan C. Schisler |Ralph S Baric |Alexandra L. Tse
AbstractEver-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that offers a greater breadth of protection against current and future VOCs would eliminate the need to reformulate COVID-19 vaccines. Here, we rationally engineer the sequence-conserved S2 subunit of the SARS-CoV-2 spike protein and characterize the resulting S2-only antigens.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →